Top

Published in:

Open Access 01-01-2018

Generation and characterization of tissue-type plasminogen activator transgenic rats

Authors: Yusuke Ito, Kengo Noguchi, Yoshiyuki Morishima, Kyoji Yamaguchi

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2018

Abstract

To address a species difference in the responsiveness to human recombinant tissue-type plasminogen activator (rt-PA) between rats and humans, tPA transgenic (Tg) rats were generated and characterized. In the rats, transcriptional regulation of tPA was designed under the control of the endogenous tPA promoter. There were no significant differences in hematological parameters between the tPA Tg and non Tg rats. Plasma tPA concentration was significantly increased and serum free PAI-1 was significantly decreased in the tPA Tg rats. Significant overexpression of tPA mRNA in five major organs was also confirmed in the tPA Tg rats. In contrast, the extent of tPA mRNA induction by pathophysiological stimuli (focal cerebral ischemia) was comparable in the two strains. Earlier increase in the plasma D-Dimer level was observed in the tPA Tg rats in a model of thromboembolism compared with the non Tg rats. On the other hand, there was no statistically significant prolongation of bleeding time in a rat model of bleeding between the two strains. rt-PA showed dose-related blood flow restoration in a rat model of thromboembolic stroke in the tPA Tg rats from a dose (1 mg/kg, i.v.) similar to clinical doses for human stroke patients. In conclusion, tPA Tg rats, in which tPA is overexpressed and endogenous fibrinolytic activity is enhanced without hemostatic abnormality, were generated. tPA Tg rats would be beneficial for the pharmacological and the toxicological evaluation of rt-PA and other various fibrinolytic enhancers.

Cesarman-Maus G, Hajjar KA (2005) Molecular mechanisms of fibrinolysis. Br J Haematol 129:307–321CrossRefPubMed

Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM et al (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44:870–947CrossRefPubMed

Wyseure T, Declerck PJ (2014) Novel or expanding current targets in fibrinolysis. Drug Discov Today 19:1476–1482CrossRefPubMed

Kuiper J, van de Bilt H, Martin U, van Berkel TJ (1995) Uptake, internalization and degradation of the novel plasminogen activator reteplase (BM 06.022) in the rat. Thromb Haemost 74:1501–1510PubMed

Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC et al (1991) Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 84:244–253CrossRefPubMed

Wu HL, Shi GY, Bender ML (1987) Preparation and purification of microplasmin. Proc Natl Acad Sci USA 84:8292–8295CrossRefPubMedPubMedCentral

Hu W, Kitano Y, Hasumi K (2003) SMTP-4D, -5D, -6D, -7D and -8D, a new series of the non-lysine-analog plasminogen modulators with a D-amino acid moiety. J Antibiot (Tokyo) 56:832–837CrossRef

Suzuki K, Muto Y, Fushihara K, Kanemoto K, Iida H, Sato E et al (2004) Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 309:607–615CrossRefPubMed

Wang YX, Zhao L, Nagashima M, Vincelette J, Sukovich D, Li W et al (2007) A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)—part I: pharmacological characterization. Thromb Haemost 97:45–53PubMed

10.

Wang YX, da Cunha V, Vincelette J, Zhao L, Nagashima M, Kawai K et al (2007) A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa)—part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 97:54–61PubMed

11.

Bird E, Tamura J, Bostwick JS, Steinbacher TE, Stewart A, Liu Y et al (2007) Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats? Thromb Res 120:549–558CrossRefPubMed

12.

Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Grønning BA et al (2015) Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol 14:575–584CrossRefPubMed

13.

Thijs VN, Peeters A, Vosko M, Aichner F, Schellinger PD, Schneider D et al (2009) Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke. Stroke 40:3789–3795CrossRefPubMed

14.

Overgaard K, Sereghy T, Pedersen H, Boysen G (1992) Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. Neuroreport 3:925–928CrossRefPubMed

15.

Haelewyn B, Risso JJ, Abraini JH (2010) Human recombinant tissue-plasminogen activator (alteplase): why not use the ‘human’ dose for stroke studies in rats? J Cereb Blood Flow Metab 30:900–903CrossRefPubMedPubMedCentral

16.

Tomkins AJ, Hood RJ, Levi CR, Spratt NJ (2015) Tissue Plasminogen Activator for preclinical stroke research: neither “rat” nor “human” dose mimics clinical recanalization in a carotid occlusion model. Sci Rep 5:16026CrossRefPubMedPubMedCentral

17.

Korninger C, Collen D (1981) Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 46:561–565PubMed

18.

An J, Zhang C, Polavarapu R, Zhang X, Zhang X, Yepes M (2008) Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood 112:2787–2794CrossRefPubMedPubMedCentral

19.

Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW et al (2003) Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9:1313–1317CrossRefPubMed

20.

Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y (2006) Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 281:2120–2127CrossRefPubMed

21.

Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M et al (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92:2756–2760CrossRefPubMedPubMedCentral

22.

Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M (1999) Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 93:2274–2281PubMed

23.

Madani R, Hulo S, Toni N, Madani H, Steimer T, Muller D et al (1999) Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 18:3007–3012CrossRefPubMedPubMedCentral

24.

Testa G, Zhang Y, Vintersten K, Benes V, Pijnappel WW, Chambers I et al (2003) Engineering the mouse genome with bacterial artificial chromosomes to create multipurpose alleles. Nat Biotechnol 21(4):443–447CrossRefPubMed

25.

Longa EZ, Weinstein PR, Carlson S, Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84–91CrossRefPubMed

26.

Yang XW, Gong S (2005) An overview on the generation of BAC transgenic mice for neuroscience research. Curr Protoc Neurosci. https://doi.org/10.1002/0471142301.ns0520s31

27.

Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB et al (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425:917–925CrossRefPubMed

28.

Oikawa K, Watanabe T, Higuchi S (2000) Comparison of drug disposition between wild-type and novel tissue-type plasminogen activator pamiteplase in rats. Drug Metab Dispos 28:1087–1093PubMed

29.

Sturgeon SA, Jones C, Angus JA, Wright CE (2006) Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of anti-thrombotic molecules in small animals. J Pharmacol Toxicol Methods 53:20–29CrossRefPubMed

30.

Rha JH, Saver JL (2007) The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 38:967–973CrossRefPubMed

31.

Wu JH, Siddiqui K, Diamond SL (1994) Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis. Thromb Haemost 72:105–112PubMed

32.

Arboix A, Alió J (2010) Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev 6:150–161CrossRefPubMedPubMedCentral

33.

Singh P, Kaur R, Kaur A (2013) Clot composition and treatment approach to acute ischemic stroke: the road so far. Ann Indian Acad Neurol 16:494–497CrossRefPubMedPubMedCentral

34.

Sena ES, Briscoe CL, Howells DW, Donnan GA, Sandercock PA, Macleod MR (2010) Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab 30:1905–1913CrossRefPubMedPubMedCentral

35.

Mokin M, Snyder KV, Siddiqui AH, Levy EI, Hopkins LN (2016) Recent endovascular stroke trials and their impact on stroke systems of care. J Am Coll Cardiol 67:2645–2655CrossRefPubMed

Title: Generation and characterization of tissue-type plasminogen activator transgenic rats
Authors: Yusuke Ito
Kengo Noguchi
Yoshiyuki Morishima
Kyoji Yamaguchi
Publication date: 01-01-2018
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 1/2018
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-017-1582-1

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Generation and characterization of tissue-type plasminogen activator transgenic rats

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Medicinal plants with antithrombotic property in Persian medicine: a mechanistic review

Structural changes of fibrinogen molecule mediated by the N-homocysteinylation reaction

Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial

Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge

Systemic lupus erythematosus and the risk of perioperative major adverse cardiovascular events

Contemporary use of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction referred to primary percutaneous coronary interventions in Poland: Data from ORPKI national registry

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page